<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1947">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629495</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20200763H</org_study_id>
    <nct_id>NCT04629495</nct_id>
  </id_info>
  <brief_title>Rapamycin - Effects on Alzheimer's and Cognitive Health</brief_title>
  <acronym>REACH</acronym>
  <official_title>Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin&#xD;
      treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage&#xD;
      Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a screening/baseline period of up to 90 days pre-study drug, with a&#xD;
      12-month (+3 day) treatment period with rapamycin, followed by a post-treatment assessment&#xD;
      completed within 14 days of the final study drug dose, and a final assessment conducted&#xD;
      6-months (+14 days) after the final study drug dose. The study duration is not expected to&#xD;
      exceed 90 weeks for participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Development or worsening of medical symptoms or problems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose level</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>A comprehensive metabolic panel is used to measure change in glucose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albumin</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>A comprehensive metabolic panel is used to measure change in albumin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in carbon dioxide or bicarbonate (CO2)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>A comprehensive metabolic panel is used to measure change in CO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in calcium</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>A comprehensive metabolic panel is used to measure change in calcium levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central nervous system penetration of rapamycin</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>A lumbar puncture and blood draw will be used to evaluate levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Cognition will be measured using the PACC5 scale. The PACC5 is a composite score comprised of measures of global cognition, memory, and executive function. The score reflects an averaged z-score. Scores range from -3 to +3 with higher scores indicating better cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. Domain scores are entered into an online algorithm and CDR-SOB score obtained by summing each of the domain box scores, ranging from 0 to 18. A lower score indicates better cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional status</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Functional status will be measured using the functional assessment scale (FAS). The FAS is completed by a collateral source and assesses ability to complete instrumental activities of daily living. The scale has 10-items and responses range from 0-3. The total score is a sum of the individual items. The total score ranges from 0 to 30 with higher scores indicating more assistance needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychiatric symptoms</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Symptoms will be evaluated using the Geriatric Depression Scale 15 Item (GDS-15). The GDS-15 is a self-report questionnaire with 15 items that have response options of 0 or 1. The total score is the sum of the individual items. The total score on the measure ranges between 0 to 15 with higher scores indicating more depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gait Speed</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Gait speed will be evaluated with an electronic gait mat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Grip Strength</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Grip strength will be evaluated with a hand dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF amyloid beta</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Cerebrospinal fluid (CSF) levels of amyloid beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral glucose metabolism</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Cerebral glucose metabolism is measured using fluorodeoxyglucose-Positron emission tomography (FDG-PET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Volumetry</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Measure of brain volumetry using MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>RAPA (rapamycin) treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>RAPA will be administered orally 1mg daily</description>
    <arm_group_label>RAPA (rapamycin) treatment group</arm_group_label>
    <other_name>Sirolimus, RAPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally once daily</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Both genders and all ethnic groups&#xD;
&#xD;
          2. Ages 55 to 89 years&#xD;
&#xD;
          3. Diagnosis of MCI or AD (Mini Mental Status Examination (MMSE): 18-30; Clinical&#xD;
             Dementia Rating Scale (CDR) = 0.5 - 1; California Verbal Learning Test III (CVLT-III)&#xD;
             Delayed Recall ≤16% based on age-adjusted norms, clinician approval)&#xD;
&#xD;
          4. Amyloid positivity based on Amyloid PET Imaging&#xD;
&#xD;
          5. Labs: Normal blood cell counts without clinically significant excursions; normal liver&#xD;
             and renal function; and glucose control (HbA1c &lt; 6.5%). Fasting lipid panel and&#xD;
             prothrombin time/prothrombin time test/international normalized ration (PT/PTT/INR)&#xD;
             within normal limits&#xD;
&#xD;
          6. A legally authorized representative (LAR) designated to sign informed consent (if&#xD;
             necessary) must attend the Screening visit and accompany the participant to all&#xD;
             remaining visits to provide reported outcomes&#xD;
&#xD;
          7. Stable dose of AD medications (Donepezil, rivastigmine, Memantine, galantamine) for at&#xD;
             least three months is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes (HBA1c≥6.5% or antidiabetic medications)&#xD;
&#xD;
          2. History of skin ulcers or poor wound healing&#xD;
&#xD;
          3. Current tobacco or illicit drug use or alcohol abuse&#xD;
&#xD;
          4. Use of anti-platelet or anti-coagulant medications other than aspirin&#xD;
&#xD;
          5. Current medications that affect cytochrome 450 3A4 (CYP3A4)&#xD;
&#xD;
          6. Immunosuppressant therapy within the last year&#xD;
&#xD;
          7. Chemotherapy or radiation treatment within the last year&#xD;
&#xD;
          8. Current or chronic history of liver or kidney disease or known hepatic or biliary&#xD;
             abnormalities&#xD;
&#xD;
          9. Untreated hypertriglyceridemia (fasting triglycerides &lt; 250 mg/dl)&#xD;
&#xD;
         10. Current or chronic history of pulmonary disease or abnormal pulse oximetry (&lt;90%)&#xD;
&#xD;
         11. Chronic heart failure&#xD;
&#xD;
         12. Pregnancy or lactation&#xD;
&#xD;
         13. Recent history (past six months) of myocardial infarction, active coronary artery&#xD;
             disease, intestinal disorders, stroke, or transient ischemic attack&#xD;
&#xD;
         14. Significant neurological conditions other than AD or MCI&#xD;
&#xD;
         15. Poorly controlled blood pressure (systolic BP&gt;160, diastolic BP&gt;90 mmHg - based on two&#xD;
             readings)&#xD;
&#xD;
         16. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal,&#xD;
             malignant, and/or severe mental illness&#xD;
&#xD;
         17. History of, or MRI, or CT positive for, any space occupying lesion, including mass&#xD;
             effect or abnormal intracranial pressure, which would indicate contraindications to&#xD;
             lumbar puncture&#xD;
&#xD;
         18. Organ transplant recipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudha J Seshadri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitzi J Gonzales, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitzi Gonzales, Phd</last_name>
    <phone>210-450-9047</phone>
    <email>gonzalesm20@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Floyd A Jones</last_name>
    <phone>210-450-3158</phone>
    <email>jonesfa@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitzi Gonzales, PhD</last_name>
      <phone>210-450-9047</phone>
      <email>gonzalesm20@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Floyd A Jones</last_name>
      <phone>(210) 450-3518</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>October 10, 2022</last_update_submitted>
  <last_update_submitted_qc>October 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Mitzi Gonzales, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>Alzheimer's disease biomarkers</keyword>
  <keyword>Neuroimaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>At study completion</ipd_time_frame>
    <ipd_access_criteria>Through journal publication</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

